Navigation Links
Time to tumor growth helps predict survival benefit of Bevacizumab for patients with metastatic colorectal cancer
Date:5/8/2013

ST. LOUIS, MO May 8, 2013 Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer. These results are now published online in the Journal of Clinical Oncology. A copy of the results can be obtained here, together with a commentary by Michael Maitland, MD, Ph.D., assistant professor of Medicine in the Section of Hematology/Oncology, and associate director, Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago Medicine, Chicago, IL.

Researchers estimated several tumor-size response metrics using longitudinal tumor-size models and data from two Phase III clinical trials, which compared bevacizumab with chemotherapy versus chemotherapy alone as first-line therapy for colorectal cancer. Trial participants included 923 Western and 203 Chinese patients. Baseline prognostic factors and the tumor-size metric estimates were assessed in multivariate models to predict overall survival. Multiple simulations of the Phase III studies were used to test the models' predictive capabilities.

Time to tumor growth proved to be the best metric for predicting overall survival. The proposed model worked equally well when predicting overall survival rates for the Western and Chinese patients and as such could be used to support drug development decisions in either population.

Ren Bruno, Ph.D., managing director of Certara's Pharsight Consulting Services Europe, and senior author of the paper, said: "This approach of combining modeling with longitudinal tumor-size data may contribute to improved design and analysis of more informative early-stage clinical studies (Phase Ib, II). It could also enable researchers to select the most promising treatments and reduce the high attrition rate in Phase III oncology studies."

Robert Powell, PharmD, former senior advisor at Roche China, and co-author of the paper, added: "It is important to know whether patients in a new market (e.g., China, India, Brazil) will be similar to patients in the original US or EU New Drug Application (NDA). While pharmaceutical companies usually assume patients from different regions are the same, there is emerging evidence that they might be different with regard to efficacy, safety and dose response. This type of analysis helps better define Chinese colon cancer response relative to Western patients. Roche performed this combined Chinese and US NDA study analysis to learn whether Chinese patients responded similarly to Western patients so they can use this information to plan future trials. Likewise knowing these results will be important to local regulatory agencies such as the China Food and Drug Administration in this case."


'/>"/>

Contact: Lisa Osborne
lisa@ranahealth.com
206-992-5245
Rana Healthcare Solutions LLC
Source:Eurekalert

Related medicine news :

1. Improved Stem Cell Line May Avoid Tumor Risk: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Dental X-Rays May Be Linked to Benign Brain Tumors
4. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
5. Brain Tumor Vaccine Shows Promise in Early Trial
6. Kidney Cancer Patients Fare Better With Tumor Removal Only
7. IBN discovers human neural stem cells with tumor targeting ability
8. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
9. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
10. New surgical technique for removing inoperable tumors of the abdomen
11. Combination of 2 drugs reverses liver tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2019)... ... ... Yes, the Millennials love their Bluetooth earbuds and Alexa smart speakers. But according ... is also finding a home in senior living communities. , The 2018 Active-Aging ... organizations that work with older adults about their adoption of technology over a time ...
(Date:1/14/2019)... ... , ... Trees can be overweight too! Giroud Tree and Lawn ... is a great time to clean things up on the property! , Health and ... during windy or icy storms. The crown of the tree should be pruned to ...
(Date:1/13/2019)... ... January 12, 2019 , ... ... (YPC) in conjunction with Temple University hosted a continuing education (CEU) event entitled, ... The event aimed to create a series of talks to help develop ...
(Date:1/11/2019)... ... 2019 , ... Ms. Barrios, a first generation immigrant from ... Andrews and others engaged in a systematic pattern of discrimination against Latina and ... race and by the color of their skin, and directed Ms. Barrios, a ...
(Date:1/10/2019)... ... January 10, 2019 , ... Net-Translators, an ... with MD101, a regulatory consulting company that serves the medical industry. The companies ... companies in the medical device and healthcare industries. Based in France, they join ...
Breaking Medicine News(10 mins):
(Date:1/15/2019)... ... January 15, 2019 , ... ... screening, compliance and credentialing solutions, announces it was recently acquired by Cisive, ... Cisive caters to the complex challenges and program needs of large enterprises ...
(Date:1/15/2019)... ... January 15, 2019 , ... ... penicillin allergy in their medical record, studies have shown that over 95% can ... reducing the risk of infection with dangerous resistant pathogens such as Clostridium difficile ...
(Date:1/14/2019)... , ... January 15, 2019 , ... Sigma Theta Tau ... (AJN) Book of the Year Awards. These awards are regarded as one of the ... 49th year, the AJN Book of the Year competition has recognized Sigma for the ...
Breaking Medicine Technology: